← Leaderboards
Joseph Felix Nowoslawski
Jsk Therapeutics, Inc.
$1,998,606
Attributed
$1,998,606
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.4K · FY2017–18$1M$750K$500K$250K$0
'17
'18
Funding mix
By agency
NIH$1,998,606 · 1
By mechanism
R44$1,998,606 · 1
Top collaborators
No co-investigators on record.
Most similar at Jsk Therapeutics, Inc.
Same institution · by research overlap
- Gregory John Johnson$87,519
- Sudhir Sahasrabudhe$309,189
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAngiogenesis InhibitorsAnimalsAnalytical MethodAntioxidantsBaseBortezomibCancer CellCancer TherapyCanis FamiliarisCapitalCardiovascular SystemCellsClinical DevelopmentCollaborationsCommercializationCyclic GmpCytarabineCytotoxicDevelopment PlansDinitrophenylDoseDrug DesignDrug Usage